Introduction
Akums Drugs and Pharmaceuticals Limited, a prominent name in the pharmaceutical industry, is set to launch its Initial Public Offering (IPO). This guide provides an in-depth look into the details of the IPO, including its structure, timeline, and key financial metrics.
🗓️ IPO Schedule
📊 Issue Breakdown
IPO Details
Reservation
Lot Size
Investors can bid for a minimum of 22 shares and in multiples thereof. Below is the minimum and maximum investment by retail investors and HNIs:
💼 Company Overview
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a leading contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. The company specializes in product development, manufacturing, R&D of formulations, regulatory dossier preparation, and testing services. Additionally, Akums manufactures branded drugs and active pharmaceutical ingredients (APIs).
Key Features
Employee Overview
As of September 30, 2023, Akums employed 16,463 people, including 7,211 full-time employees and 9,252 contract employees.
💹 Financial Performance
Financial Information (Restated Consolidated)
Key Financial Metrics (in ₹ Crore)
Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
---|---|---|---|
Assets | 3,516.37 | 3,266.53 | 3,069.05 |
Revenue | 4,212.21 | 3,700.93 | 3,694.52 |
Profit After Tax | 0.79 | 97.82 | -250.87 |
Net Worth | 709.50 | 717.19 | 621.98 |
Reserves and Surplus | 861.01 | 868.70 | 787.79 |
Total Borrowing | 491.56 | 536.97 | 357.95 |
Key Performance Indicators (KPI)
📈 Akums Drugs and Pharmaceuticals IPO Promoter Holding
🏢 Book Running Lead Managers and Registrar
🏢 Objects of the Issue
This IPO presents an opportunity for investors to become part of Akums Drugs and Pharmaceuticals Limited, a company with a strong foundation and significant growth potential in the pharmaceutical industry.